Fine specificity of myelin basic protein specific T cells: Implications for TCR antagonism

Anderton, Stephen M.; Manickasingham, Shivanthi P.; Burkhart, Christoph; Lowrey, Pauline; Burkhart, B A; Wraith, David C

doi:10.1016/s0165-2478(97)85935-4

Cited by 14 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors found that treatment with this APL selectively silenced pathogenic T cells and actively signaled for the recruitment of IL-4-producing T cells. Several additional studies have been published in different EAE models confirming the efficacy of APLs in inhibiting EAE [40][41][42].…”

Section: Altered Peptide Ligands (Apls)mentioning

confidence: 84%

Antigen-Specific Therapies in Multiple Sclerosis

Sospedra

Martin

2005

International Reviews of Immunology

View full text Add to dashboard Cite

During recent years, many new therapies for human autoimmune diseases such as multiple sclerosis (MS) have been considered based on promising in vitro data or animal experiments. A number of them have proceeded to early clinical testing. However, very few finally advanced to approval by the regulatory agencies and are currently available to patients. The main reasons for failure were either lack of efficacy in humans and/or unexpected and untolerable adverse events. Although previous attempts toward antigen-specific immunomodulation have often been disappointing, these difficulties have led to renewed interest in therapies that aim at reestablishing tolerance to autoantigens at the level of either T cell-mediated or antibody-mediated immune responses or both. Such antigen-specific immunotherapies offer the prospect of correcting pathological immune reactivity against autoantigens in a highly specific and effective manner and also achievement of this goal with relatively little side effects. Here we will review the various approaches that are currently being considered for antigen-specific immunotherapies in MS.

show abstract

Section: Altered Peptide Ligands (Apls)mentioning

confidence: 84%

Antigen-Specific Therapies in Multiple Sclerosis

Sospedra

Martin

2005

International Reviews of Immunology

View full text Add to dashboard Cite

show abstract

“…However, the model used in the present study seems to be ineffective at prolonging allograft survival time. The majority of studies using animal models suggest that peptides with MHC-blocking capacity inhibit the development or progression of autoimmune diseases [18,24,29,[43][44][45]. Optimizing the protocol for A1.5, such as the use of multiple applications, could enhance the inhibitory effect of the MHC-competitor analogue on allograft survival time.…”

Section: Discussionmentioning

confidence: 99%

Allogeneic core amino acids of an immunodominant allopeptide are important for MHC binding and TCR recognition

Sitaru¹,

Timmermann

Ulrichs³

et al. 2004

Human Immunology

View full text Add to dashboard Cite

“…In contrast, position 3 is the secondary TCR contact residue with certain APL providing sub-agonist stimulation. Thus the WT > 3Met > 3Thr w 3-Phe w 3Tyr hierarchy for T cell stimulation has been established [44,46]. It is worth noting that analyses of polyclonal T cell lines and another transgenic mouse bearing a different Ac1e9-reactive TCR have revealed that there is some flexibility possible in recognition of position 6 [46], but because our studies have predominantly used T cells from the Tg4 TCR transgenic mouse, the above information is relevant to this discussion.…”

Section: Modelling Molecular Mimicry Using Cns Autoimmune Diseasementioning

confidence: 99%